Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR

摘要: Luminal A breast cancer usually responds to hormonal therapies but does not benefit from chemotherapies, including microtubule-targeted paclitaxel. MicroRNAs could play a role in mediating this differential response. In study, we examined the of micro RNA 100 (miR-100) sensitivity paclitaxel treatment. We found that while miR-100 was downregulated both human primary tumors and cell lines, degree downregulation greater luminal subtype than other subtypes. The IC50 much higher basal-like lines. Ectopic expression MCF-7 line enhanced effect on cycle arrest, multinucleation, apoptosis, knockdown MDA-MB-231 compromised these effects. Similarly, overexpression effects tumorigenesis cells. Rapamycin-mediated inhibition mammalian target rapamycin (mTOR), miR-100, also sensitized cells Gene set enrichment analysis showed genes are part known paclitaxel-sensitive signature had significant correlation with samples. addition, patients lower levels worse overall survival. These results suggest plays causal determining cancers